Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 18/20 | 0.62 |
| ▸ | LTB4R2 | Q9NPC1 | 15/20 | 0.62 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806211 | 0.91 | LTB4R (0.55) | LTB4RLTB4R2 | |
| SCHEMBL6808256 | 0.91 | LTB4R (0.53) | LTB4RLTB4R2 | |
| SCHEMBL6806717 | 0.89 | LTB4R (0.54) | LTB4RLTB4R2 | |
| SCHEMBL6806236 | 0.87 | LTB4R (0.52) | LTB4RLTB4R2 | |
| SCHEMBL6802573 | 0.87 | LTB4R (0.49) | LTB4RLTB4R2 | |
| SCHEMBL6802568 | 0.87 | LTB4R (0.49) | LTB4RLTB4R2 | |
| SCHEMBL6807550 | 0.86 | LTB4R (0.51) | LTB4RLTB4R2 | |
| SCHEMBL6899650 | 0.85 | LTB4R (0.68) | LTB4RLTB4R2 | |
| SCHEMBL7638424 | 0.84 | LTB4R (0.52) | LTB4RLTB4R2 | |
| SCHEMBL8949707 | 0.84 | LTB4R (0.79) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198779-A1 | Heterocycle substituted diphenyl leukotriene antagonists | SAWYER JASON SCOTT (US) | 2004-10-07 | — | — | US | disclosed |
| US-6797723-B1 | Heterocycle substituted diphenyl leukotriene antagonists | ELI LILLY AND COMPANY | 2004-09-28 | — | — | US | disclosed |
| EP-1263743-A1 | HETEROCYCLE SUBSTITUTED DIPHENYL LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-1231939-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1231938-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001034197-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034198-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034135-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034137-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034580-A1 | HETEROCYCLE SUBSTITUTED DIPHENYL LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198779-A1 | Heterocycle substituted diphenyl leukotriene antagonists | LTB4R, LTB4R2, LTA4H | LTB4R 1/4885LTB4R2 2/4885NR1H4 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.